Search results
Results From The WOW.Com Content Network
If the lymph node or similar tissue is reactive, or otherwise benign, it should possess a mixture of kappa positive and lambda positive cells. If, however, one type of light chain is significantly more common than the other, the cells are likely all derived from a small clonal population, which may indicate a malignant condition, such as B-cell ...
Free light chains (FLCs) are immunoglobulin light chains that are found in the serum (blood) in an unbound (free) state. In recent decades, measuring the amount of free light chains (FLCs) in the blood has become a practical clinical test. FLC tests can be used to diagnose and monitor diseases like multiple myeloma and amyloidosis.
In contrast to neoplastic mantle cells (which are negative for CD23), the resting cells of physiologic mantle zone express CD23. Paradoxically, Lymphomas arising from the mantle zone are generally negative for CD23, while most B-cell chronic lymphomocytic leukaemias are positive, allowing immunohistochemistry to distinguish these conditions ...
If the red cells then agglutinate, the test is positive, a visual indication that antibodies or complement proteins are bound to the surface of red blood cells and may be causing destruction of those cells. The indirect Coombs test is used in prenatal testing of pregnant women and in testing prior to a blood transfusion. The test detects ...
Immunocytochemistry is a technique used to assess the presence of a specific protein or antigen in cells (cultured cells, cell suspensions) by use of a specific antibody, which binds to it, thereby allowing visualization and examination under a microscope. It is a valuable tool for the determination of cellular contents from individual cells.
CD38 (cluster of differentiation 38), also known as cyclic ADP ribose hydrolase, is a glycoprotein [5] found on the surface of many immune cells (white blood cells), including CD4 +, CD8 +, B lymphocytes and natural killer cells. CD38 also functions in cell adhesion, signal transduction and calcium signaling. [6]
Varlilumab is an IgG1 antibody that binds to CD27 and is an experimental cancer treatment. [6] This agonist antibody stimulates CD27 when it binds. [ 6 ] The drug is in early clinical trials and appears to stimulate T cells and increase production of cytokines such as interferon-gamma.
CD19 is widely expressed during all phases of B cell development until terminal differentiation into plasma cells. During B cell lymphopoiesis, CD19 surface expression starts during immunoglobulin (Ig) gene rearrangement, which coincides during B lineage commitment from hematopoietic stem cell. [8]